Lasermicrodissection - An important prerequisite for the molecular-genetic analysis of bladder cancer

Pathology Research and Practice

Volumn 199, Issue 6, 2003, Pages 355-362

  Stoehr, Robert ^a   Wild, Peter ^a   Hartmann, Arndt ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bladder cancer; Clonality; Lasermicrodissection; LOH analysis; Prenoplastic lesions

Indexed keywords

DNA;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CARCINOMA IN SITU; CELL POPULATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYSTECTOMY; DYSPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; LASER; LASER MICRODISSECTION; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRECANCER; RELIABILITY; SEQUENCE ANALYSIS; TISSUE SECTION; TUMOR CELL; UROGENITAL SYSTEM;

EID: 0042063849     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00431     Document Type: Article

References (35)

1. Bohm M, Kirch H, Otto T, Rubben H, Wieland I (1997) Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus on 5pl3-12 is a prognostic marker of tumor progression. Int J Cancer 74: 291-295
2. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D (2000) Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89: 514-518
3. Cordon-Cardo C, Cote RJ, Sauter G (2000) Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Nephrol Suppl 205: 82-93
4. Czerniak B, Li L, Chaturvedi V, Ro JY, Johnston DA, Hodges S, Benedict WF (2000) Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 27: 392-402
5. Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, Jauch KW, Hofstaedter F, Ruschoff J (1999) Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 154: 83-95
6. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nature Genet 33: 90-96
7. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M, Grone HJ (2002) Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180
8. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
9. Hafner C, Knuechel R, Stoehr R, Hartmann A (2002) Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101: 1-6
10. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, Hofstaedter F, Hartmann A (2001) Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20: 4910-4915
11. Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F, Knuechel R (2000) Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 80: 709-718
12. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62: 809-818
13. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R (1999) Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154: 721-727
14. Hofstadter F, Delgado R, Jaske G, Judmaier W (1986) Urothelial dysplasia and carcinoma in situ of the bladder. Cancer 57: 356-361
15. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL (1994) Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 30: 1621-1625
16. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. J Clin Pathol: Mol Pathol 54: 215-221
17. Koss LG, Tiamson EM, Robbins MA (1974) Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. J Am Med Assoc 227: 281-286
18. Kurth K (1997) Natural history and prognosis of untreated and treated superficial bladder cancer. In: Pagano F, Fair WR (Eds) Superficial bladder cancer, pp 42-56. Isis Medical Media, Oxford, UK
19. Mostofi FK, Sobin LH Torloni H (1973) Histological typing of urinary bladder tumours. Geneva: World Health Organization
20. Mostofi FK, Davis CJ, Sesterhenn IA (1999) Histological typing of urinary bladder tumours. In: Mosteti FW, Davis CJ, Sesterhenn IA (Eds) World Health Organization-International Histological Classification of Tumours. Springer Verlag, Berlin
21. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R, Hartmann A (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199: 50-57
22. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D (1995) Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55: 5213-5216
23. Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P, Oliveira J, Criado B, Lopes C -(2003) Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 105:267-272
24. Sarma KP (1981) Genesis of papillary tumours: histological and microangiographic study. Br J Urol 53: 228-236
25. Sauter G,Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, et al. (1994) Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol 144: 756-766
26. Schlegel J, Bocker T, Zirngibl H, Hofstadter F, Ruschoff J (1995) Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch 426: 223-227
27. Simon R, Eltze E, Schafer KL, Burger H, Senijonow A, Hertle L, Dockhorn-Dworniczak B, Terpe HJ, Bocker W (2001) Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 61: 355-362
28. Simon R, Sauter G (2002) Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 30: 1265-1272
29. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-788
30. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG (1998) Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160 (Pt 1): 645-659
31. Stoehr R, R Knuechel, Hartmann A (2002) Genetic alterations in flat urothelial neoplasia. Histopathology 41 (Supplement): 414-419.
32. Stoehr R, Hartmann A, Hiendlmeyer E, Murle K, Wieland W, Knuechel R (2000) Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis. Pathobiology 68: 165-172
33. Stoehr R, Knuechel R, Boecker J, Blaszyk H, Schmitt R, Filbeck T, Hofstaedter F, Hartmann A (2002) Histologicgenetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab Invest 82:1553-1561
34. Van Rhijn BWG, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC (2003) Combined microsatellite and FGFR3 mutation analysis enables a high sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9: 257-263
35. Van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61: 1265-1268